CN Patent

CN121866055A — 阿达格拉西布盐的结晶形式

Assigned to Milady Treatment Co · Expires 2026-04-14 · 0y expired

What this patent protects

本发明涉及KRas G12C抑制剂2‑[(2b)‑4‑[7‑(8‑氯‑1‑萘基)‑2‑[[(2 S )‑1‑甲基吡咯烷‑2‑基]甲氧基]‑6,8‑二氢‑5 H ‑吡啶并[3,4‑ d ]嘧啶‑4‑基]‑1‑(2‑氟丙‑2‑烯酰基)哌嗪‑2‑基]乙腈的盐的结晶形式、包含所述结晶形式的药物组合物、制备所述结晶形式的方法及其使用方法。

USPTO Abstract

本发明涉及KRas G12C抑制剂2‑[(2b)‑4‑[7‑(8‑氯‑1‑萘基)‑2‑[[(2 S )‑1‑甲基吡咯烷‑2‑基]甲氧基]‑6,8‑二氢‑5 H ‑吡啶并[3,4‑ d ]嘧啶‑4‑基]‑1‑(2‑氟丙‑2‑烯酰基)哌嗪‑2‑基]乙腈的盐的结晶形式、包含所述结晶形式的药物组合物、制备所述结晶形式的方法及其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121866055A
Jurisdiction
CN
Classification
—
Expires
2026-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Milady Treatment Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.